1 Noradrenaline (NA) and adrenaline (Ad) are modulators of cytokine production. Here we investigated the role of these neurotransmitters in the regulation of macrophage in¯ammatory protein (MIP)-1a expression. 2 Pretreatment of RAW 264.7 macrophages with NA or Ad decreased, in a concentration-dependent manner (1 nM ± 100 mM), MIP-1a release induced by bacterial lipopolysaccharide (LPS 10 ng ml 71 LPS). The eect of NA was reversed by the selective b-adrenoceptor antagonist propranolol (10 mM), but not by the a-adrenoceptor antagonist phentolamine (10 mM). 3 In the concentration range of 10 nM ± 10 mM, isoproterenol, a b-adrenoceptor agonist, but not phenylephrine (a selective a 1 -adrenoceptor agonist) or UK-14304 (a selective a 2 -adrenoceptor agonist) mimicked the inhibitory eects of catecholamines on MIP-1a production. Increases in intracellular cyclic adenosine monophosphate, elicited either by the selective type IV phosphodiesterase inhibitor rolipram (0.1 ± 10 mM), or by prostaglandin E 2 , (10 nM ± 10 mM) decreased MIP-1a release, suggesting that increased cyclic AMP may contribute to the suppression of MIP-1a release by b-adrenoceptor stimulation. 4 Northern blot analysis demonstrated that NA (100 nM ± 10 mM), Ad, isoproterenol, as well as rolipram (100 nM ± 10 mM) decreased LPS-induced MIP-1a mRNA accumulation. NA and Ad (1 ± 100 mM) also decreased MIP-1a production in thioglycollate-elicited murine peritoneal macrophages. 5 Pretreatment of mice with either isoproterenol (10 mg kg 71 , i.p.) or rolipram (25 mg kg 71 , i.p.) decreased LPS-induced plasma levels of MIP-1a, while propranolol (10 mg kg 71 , i.p.) augmented the production of this chemokine, con®rming the role of a b-adrenoceptor mediated endogenous catecholamine action in the regulation of MIP-1a production in vivo. 6 Thus, based on our data we conclude that catecholamines are important endogenous regulators of MIP-1a expression in in¯ammation.
Introduction
The CC-chemokine macrophage in¯ammatory protein-1a (MIP-1a) was originally identi®ed as a product of endotoxinstimulated RAW 264.7 macrophages (Davatelis et al., 1988; Wolpe et al., 1988) and was subsequently shown to be produced by a number of cell types including neutrophils (Kasama et al., 1993) , activated lymphocytes (Schall et al., 1992) , and ®broblasts (Koch et al., 1994) . MIP-1a is a member of the chemokine gene superfamily and is chemotactic for macrophages and T lymphocytes. In addition to its chemotactic activity, MIP-1a potently activates macrophages to secrete TNF-a, interleukin (IL)-1, and IL-6 (Fahey et al., 1992) . MIP-1a has been shown to importantly contribute to the lung leukocyte accumulation, capillary leak, acute lung injury, and mortality in endotoxemia, in¯uenza virus-infected mice, and by infection with group A Streptococci (Cook et al., 1995; Shanley et al., 1995 Shanley et al., , 1996 Standiford et al., 1995) . We have recently shown that systemic appearance of MIP-1a can be also induced by the superantigen staphylococcal enterotoxin B (HaskoÂ et al., 1998c) . MIP-1a has also been implicated as a pathogenic factor in various other in¯ammatory states such as rheumatoid arthritis (Kasama et al., 1995) , experimental autoimmune encephalomyelitis (Karpus et al., 1995) , glomerulonephritis (Natori et al., 1997) , and asthma (Strieter et al., 1996) . Recently, it was shown that MIP-1a released by LPSstimulated human macrophages inhibited HIV replication both in macrophages and T lymphocytes (Verani et al., 1997) .
The catecholamines NA and Ad are among the most important stress hormones that can regulate macrophage function. Cells of the monocyte/macrophage line express catecholamine receptors and respond to occupation with selective ligands of these G-protein coupled cell surface structures by altering such diverse activities as cytokine production (Spengler et al., 1990 (Spengler et al., , 1994 Severn et al., 1992; Pastores et al., 1996; van der Poll et al., 1996) , free radical release (Feinstein et al., 1993; SzaboÂ et al., 1997; HaskoÂ et al., 1998a) , migration (Pick, 1972) , or tumoricidal activity (Ko & Dunegan, 1985) . In¯ammatory processes mediated by macrophage products induce the release of both NA and Ad (Hall & Hodge, 1971; Dunn, 1992; Besedovsky & Del Rey, 1996) from the sympathetic nervous system, providing the means for the feedback regulation of macrophage function.
In the present study, we examined, whether catecholamines regulate in vitro MIP-1a production in various cellular systems including RAW 264.7 macrophages, primary peritoneal macrophages, and in vivo production in endotoxemic mice. We report that catecholamines exert a substantial inhibitory activity on MIP-1a production both in vitro and in vivo demonstrating a novel mechanism whereby the sympathetic nervous system can modulate the immune response.
Methods

Mice
Male BALB/c mice (8 weeks) were purchased from Charles River Laboratories (Wilmington, MA, U.S.A.).
Materials
DMEM was purchased from Life Technologies (Grand Island, NY, U.S.A.). LPS from Escherichia coli 055:B5, prostaglandin (PG)E 2 , (7) adrenaline, (7) 
In vitro experiments
Cell culture The mouse macrophage cell line RAW 264.7 was grown in DMEM supplemented with 10% FCS, 100 U ml 71 penicillin, and 100 mg ml 71 streptomycin in a humidi®ed atmosphere of 95% air and 5% CO 2 . Cells were cultured in 96well plates (200 ml medium per well) until 80% con¯uence. For MIP-1a measurement in RAW macrophages, cells were treated with various concentrations of NA, Ad, rolipram, PGE 2 or selective a-and b-adrenoceptor agonists 30 min before the addition of 10 ng ml 71 LPS and supernatants were taken at various time points after LPS. Selective antagonists of adrenoceptors were added 30 min before NA. MIP-1a was determined by ELISA as described below.
Preparation of peritoneal macrophages Mice were injected intraperitoneally (i.p.) with 1 ml of 1.5 % thioglycollate (TG) and peritoneal cells were harvested 3 ± 4 days later. The cells were plated on 96-well plastic plates at 1 million cells ml 71 and incubated in DMEM for 2 h at 378C in a humidi®ed 5% CO 2 incubator. Non-adherent cells were removed by rinsing the plates three times with 5% dextrose in PBS. Cells were then stimulated with LPS (10 ng ml 71 ) for 24 h.
Measurement of mitochondrial respiration Mitochondrial respiration, an indicator of cell viability, was assessed by the mitochondria-dependent reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) to formazan (HaskoÂ et al., 1996) . Cells in 96-well plates were incubated with MTT (2610 71 mg ml 71 ) for 60 min at 378C. Culture medium was removed by aspiration, and cells were solubilized in dimethylsulphoxide (100 ml). The extent of reduction of MTT to formazan within cells was quantitated by measurement of optical density at 550 nm (OD 550 ) using a Spectramax microplate reader.
Northern blot analysis Total cellular RNA was extracted from each well using a guanidinium isothiocyanate/chloroform based technique (TRIZOL; Gibco BRL, U.S.A.), followed by isopropanol precipitation. Cytoplasmic RNA (10 ± 15 mg) was fractionated on a 1% formaldehyde gel and transferred to a nylon membrane. The cDNA for rat MIP-1a, which was cloned from IgG immune complex injured lungs (Shanley et al., 1995) , has been shown to cross-hybridize with mouse MIP-1a was used for Northern blot analysis. This cDNA was radiolabelled with [ 32 P]-dCTP (speci®c activity, 3,000 Ci mM 71 ; NAN DuPont) by random priming (Pharmacia, Piscataway, NJ, U.S.A.). Radioactivity of the probe was determined by scintillation counting and 1.5610 7 c.p.m. were applied to the Northern blot and hybridization was performed at 428C for 15 h. The hybridized membranes were serially washed at 528C with 26sodium citrate, sodium chloride, 0.1% SDS (26SSC) solution. Autoradiography was done on either Kodak X-OMAT-AR ®lm or phosphoimaging screens. After probing for MIP-1a, membranes were stripped with boiling 5 mM EDTA and rehybridized with a [ 3 P]-radiolabelled oligonucleotide probe for 18S ribosomal RNA for determination of equal loading.
In vivo experiments
Experimental design for plasma MIP-1a measurements Male BALB/c mice were injected i.p. with isoproterenol, propranolol, or CH-38083 in a volume of 0.1 ml 10 71 g body weight. Thirty minutes later, they were challenged with 5 mg kg 71 of LPS administered i.p. Animals were anaesthetized at various time-points after LPS treatment and blood was redrawn by the retroorbital route. The blood was then centrifuged for 10 min at 48C. The plasma was stored at 7708C until assayed.
MIP-1a assay
MIP-1a levels in plasma and cell culture supernatants were determined by an ELISA kit that is speci®c against murine MIP-1a (R&D, Minneapolis, MN, U.S.A.). Plates were read at 450 nm by the Spectramax 250 microplate reader (Molecular Devices, Sunnyvale, CA, U.S.A.). The detection limit was 1.5 pg ml 71 for MIP-1a. The assay was performed according to the manufacturer's instructions.
Data analysis All values in the Figures and text are expressed as means +s.e. mean of n observations, where n represents the number of wells studied (6 ± 9 wells from 2 ± 3 independent experiments). Data sets were examined by one-and two-way analysis of variance. After performing the ANOVA, a post-hoc analysis was performed, whereby individual group means were compared with Student's unpaired t-test. A P-value less than 0.05 was considered signi®cant. Where Northern blots are presented, results shown are representative of at least three independent experiments performed on dierent experimental days.
Results
NA and Ad inhibit MIP-1 a production by RAW 264.7 macrophages Low levels of MIP-1a were detectable without stimulation in RAW macrophages (not shown). LPS (10 ng ml 71 ) induced a 10 ± 20 fold elevation of the secretion of MIP-1a by 3 h after LPS exposure (Figure 1) , which further increased by 24 h (not shown). The 3 h time point was chosen to examine the eect of adrenergic agonists and antagonists on the LPS-elicited increase in MIP-1a, because this time point represented maximal MIP-1a plasma levels in the in vivo studies (see below), thus allowing for a good comparison of in vitro to in vivo results. Pretreatment of the cells with NA or Ad 30 min before the addition of LPS caused a concentration-dependent reduction of MIP-1a formation as assessed at the 3 h ( Figure  1 ) and 24 h time-points (not shown). To investigate which adrenoceptors were responsible for the eects of catecholamines, cells were pretreated with NA in the presence of the nonselective a-adrenoceptor antagonist phentolamine (10 mM) or the nonselective b-adrenoceptor blocker propranolol (10 mM) and MIP-1a levels 3 h after LPS were determined. Figure 2 shows that propranolol, but not phentolamine prevented the eect of the non-selective adrenergic agonist NA, demonstrating that the inhibition of MIP-1a production is a b-receptor mediated process. Propranolol or phentolamine alone did not aect MIP-1a production by LPS-stimulated cells (Figure 2 ).
To con®rm that b-adrenoceptors mediated the eect of catecholamines, the eects of the selective b-adrenoceptor agonist isoproterenol, the selective a 1 -adrenoceptor agonist phenylephrine, or the selective a 2 -adrenoceptor agonist UK-14304 were tested on the LPS-induced production of MIP-1a. Figure 3 shows that isoproterenol, but not phenylephrine or UK-14304 decreased MIP-1a production in a concentrationdependent manner, corroborating that b-adrenoceptors play a central role in the suppression of MIP-1 formation by catecholamines. The moderate decrease in MIP-1a production by phenylephrine and UK-14304 at their highest concentrations is likely to represent a non-speci®c action of these agonists on badrenoceptors at the highest dose used. None of the above agonists or antagonists of adrenoceptors used decreased cell viability as determined by the MTT test (not shown).
Role of elevated cyclic adenosine monophosphate (cyclic AMP) levels in the inhibition of MIP-1a production by b-adrenoceptor stimulation
Since the main pathway whereby activation of b-adrenoceptors produces its eects is related to the elevation of intracellular cyclic AMP levels and changes in intracellular cyclic AMP concentrations are known to alter cytokine production (HaskoÂ et al., 1998b; Pastores et al., 1996) , we next determined the eect other agents which elevate intracellular cyclic AMP levels on LPS-stimulated MIP-1a levels in RAW 264.7 cells. Both PGE 2 which augments cyclic AMP by binding to its own receptor, and rolipram, which causes cyclic AMP elevation by inhibiting the cyclic AMP degrading enzyme phosphodiesterase, inhibited, in a concentration-dependent manner, the release of MIP-1a ( Figure 4 ). This observation suggests that the inhibition of MIP-1a production by b-adrenoceptor stimulation is most probably due to its ability to elevate intracellular cyclic AMP. Again, neither PGE 2 nor rolipram aected cell viability as determined by the MTT assay (not shown).
Catecholamines inhibit MIP-1a release by TG-elicited peritoneal adherent cells LPS (10 mg ml 71 ) induced a *1.5 ± 2 fold elevation of MIP-1a in thioglycollate (TG) elicited macrophages over baseline levels measured 24 h after the addition of LPS, which were relatively high, probably owing to the activation caused by TG. Pretreatment of the cells with NA or Ad decreased the degree of LPS-induced MIP-1a production ( Figure 5 ). Both catecholamines also suppressed basal MIP-1a release by these cells (Figure 5 ).
Eects of catecholamines on MIP-1a mRNA in RAW cells
In order to determine whether inhibition of MIP-1a observed with adrenergic stimulation was at the transcriptional level, steady state mRNA levels were determined under similar in vitro conditions as described above. In preliminary studies we established that peak transcript levels for MIP-1a in LPSstimulated RAW 264.7 cells occurred between 1 and 3 h. Pretreatment of RAW cells with noradrenaline (100 nM ± 10 mM, 30 min) resulted in a signi®cant decrease in mRNA levels determined at 2 h post-LPS (Figure 6a ). Similar results were found with adrenaline (not shown). Thus, the molecular level of MIP-1a inhibition by catecholamines appears to be at the transcriptional level.
The observation that pretreatment of RAW cells with both isoproterenol (100 nM ± 10 mM, 30 min) (not shown) and rolipram (100 nM ± 10 mM, 30 min pre-treatment) caused a dose-dependent decrease in steady state mRNA levels for MIP-1a (Figure 6b) is consistent with the proposal that inhibition by Ad and NA of MIP-1a production is mediated via b-adrenoceptor stimulation and as a result of increased cyclic AMP levels.
Overall, there was a fairly good agreement in the degree of the inhibition by MIP-1a protein and MIP-1a mRNA expression by the adrenergic agonists or rolipram. However, the degree of inhibition of MIP-1a mRNA levels and the protein levels did not always correspond to each other. For instance, using the ELISA method, we found that rolipram (at 1 mM) markedly inhibited MIP-1a protein production ( Figure  4) , while the inhibition of MIP-1a mRNA production was less pronounced at this concentration (Figure 6b) . Dierences in the time of the measurements (protein was measured at 3 h, mRNA at 2 h post-LPS), and/or dierences in the sensitivity of the two assays used (ELISA vs Northern blotting) may be responsible for these dierences.
Stimulation of b-adrenoceptors inhibits MIP-1a production in vivo
Intraperitoneal injection of 5 mg kg 71 LPS into BALB/c mice induced an elevation of the plasma MIP-1a level, which peaked at 2 h, and returned near baseline levels by 8 h (Figure 7a ). Pretreatment of the mice with isoproterenol 30 min before the injection of LPS resulted in a signi®cant suppression of plasma MIP-1a levels at 2 and 4 h (Figure 7a ). Conversely, pretreatment of animals with propranolol 30 min before LPS brought about a signi®cant enhancement of plasma MIP-1a level (Figure 7b ). Collectively, these data suggest that endogenous catecholamines decrease MIP-1a production via b-adrenoceptors.
Although, the results of the in vitro experiments suggest that a 2 -adrenoceptors on macrophages are not involved in the regulation of MIP-1a release by catecholamines, the possible role of presynaptic a 2 -adrenoceptors on catecholaminereleasing nerve terminals was tested by injecting the selective a 2 -adrenoceptors antagonist CH-38083 (HaskoÂ et al., 1995ab; Elenkov et al., 1995) . Pretreatment of the animals with CH-38083 provoked a signi®cant decrease of the plasma MIP-1a level (Figure 7b ). This is consistent with the notion that a 2adrenoceptor blockade enhances NA release from the sympathetic nerve terminals of lymphoid organs (HaskoÂ et al., 1995a; Vizi et al., 1995) and the increased stimulation by NA released in excess of postsynaptic (macrophage) badrenoceptors suppresses the production of cytokines HaskoÂ & SzaboÂ , 1998) . Finally, rolipram decreased plasma MIP-1a levels con®rming that elevation of cyclic AMP suppresses MIP-1a production in vivo (Figure 7b ).
Discussion
Over the past two decades a large body of evidence has accumulated demonstrating that immune cell function is under the control of the central nervous system (Madden et al., 1995; Vizi et al., 1995; Besedovsky & Del Rey, 1996; HaskoÂ & SzaboÂ , 1998) . Signalling through the sympathetic nervous system represents one of the main pathways whereby this regulatory action is accomplished. The most important transmitters to relay information from the sympathetic nervous system to the cellular elements of the immune system are the catecholamine neurotransmitters NA and Ad. These molecules have been shown to be released in the vicinity of immune cells upon axonal action potential of sympathetic nerve ®bres (HaskoÂ et al., 1995a; Vizi et al., 1995) . Catecholamine release generally occurs in response to stressful conditions caused by cognitive stimuli or non-cognitive stimuli, such as the immune response itself (Besedovsky & Del Rey, 1996) . A highly sensitive immunological target for transmitters of the sympathetic nervous system is the mononuclear phagocyte. It is well established that the production of in¯ammatory mediators by the monocytes/macrophages is responsive to catecholamine action. Tumour necrosis factor (TNF)-a was the ®rst cytokine whose production was shown to be regulated by occupation of a or b-adrenergic receptors by catecholamines (Spengler et al., 1990; Hu et al., 1991; Severn et al., 1992) . Subsequently, a whole array of other cytokines have been demonstrated to be in¯uenced by adrenergic receptor stimulation both in vitro and in vivo (Elenkov et al., 1996; van der Poll et al., 1996; SzaboÂ et al., 1997; HaskoÂ et al., 1998a) . The present study demonstrates for the ®rst time that classical transmitters of the sympathetic nervous system regulate the production of the CC chemokine MIP-1a. Our results with the RAW 264.7 macrophages and thioglycollate-elicited peritoneal adherent cells show that both catecholamines inhibit the production of this proin¯ammatory mediator, con®rming the predominantly anti-in¯ammatory activity of catecholamines. The inhibitory action of NA was prevented by the selective b-blocker propranolol, while aadrenergic blockade by phentolamine was without eect. Furthermore, stimulation of b-adrenoceptors by the selective b agonist isoproterenol, but not with the selective a 1 agonist phenylephrine or the a 2 agonist UK-14304, mimicked the inhibitory eect of NA and Ad. Together, these data implicate the b-adrenoceptor as the predominant substrate for mediating the inhibitory eect of catecholamines on MIP-1a production.
In various cell types, including macrophages, the main intracellular second messenger for b-adrenergic receptors is cyclic AMP (Severn et al., 1992; van der Poll et al., 1997; HaskoÂ et al., 1998a) . Since PGE 1 (Martin & Dorf, 1991) , PGE 2 (VanOtteren et al., 1994, this study), a cell permeable analog of cyclic AMP (VanOtteren et al., 1994) , and the phosphodiesterase inhibitor rolipram (this study) all suppress MIP-1a expression, it can be proposed that enhanced levels of intracellular cyclic AMP caused the decrease in MIP-1a secretion by b-adrenergic activation. In this respect, the regulation of MIP-1a production is similar to that of TNF-a, which is also suppressed by b-adrenergic stimulation via cyclic AMP (Severn et al., 1992; HaskoÂ et al., 1998a) . A further similarity is that both TNF-a (Spengler et al., 1989; Ignatowsky et al., 1996) and MIP-1a (Martin & Dorf, 1991 , VanOtteren et al., 1994 ) are regulated at the transcriptional level by b-adrenoceptor stimulation and/or elevated cyclic AMP levels.
In line with our in vitro observations, b-adrenergic stimulation with isoproterenol decreased MIP-1a production in vivo. Furthermore, b-adrenergic blockade with propranolol augmented MIP-1a plasma levels, providing evidence for an endogenous regulatory mechanism involving b-adrenoceptor stimulation by catecholamines released from the sympathetic nervous system. However, inhibition of a 2 -adrenoceptors suppressed MIP-1a plasma levels, while the in vitro studies showed no evidence for the presence of functional a 2adrenoceptors on the macrophages. This dierence can be explained by taking into account that presynaptic nerve terminals are equipped with inhibitory a 2 -adrenoceptors and blockade of these receptors have been shown to enhance NA release (HaskoÂ et al., 1995a . Therefore, the augmented release of NA by blockade of presynaptic receptors can cause an increased stimulation of postsynaptic (macrophage) b-adrenoceptors, resulting in a decreased production of MIP-1a. Such a mechanism has been shown to account for the decrease in TNF-a production in mice treated with a 2adrenoceptor antagonists (HaskoÂ et al., 1995b; Pastores et al., 1996; HaskoÂ & SzaboÂ , 1998) .
In summary, our results demonstrate for the ®rst time that catecholamines inhibit MIP-1a production. The site of the regulation is transcriptional, and the mechanism is likely to involve increased intracellular cyclic AMP mediated by badrenergic stimulation. Our current observations may demonstrate an additional mode of the immunosuppressive action of b-adrenergic stimulation. Our current results may have relevance for a variety of pathophysiological states such as experimental autoimmune encephalomyelitis or asthma, where increased MIP-1a expression has been shown to contribute to disease development (Karpus et al., 1995; Strieter et al., 1996) and b-adrenergic stimulation is known to ameliorate the course of the disease (Twentyman et al., 1990; Wiegmann et al., 1995) .
